Rejuva Gene Therapy

About Fractyl Health

Fractyl Health's mission is to prevent, reverse, and eradicate obesity and type 2 diabetes by developing durable, organ-targeted therapies that address root causes rather than symptoms. Its key achievement is the development of the Revita DMR system, an outpatient endoscopic procedure with positive clinical data for weight maintenance post-GLP-1 therapy, now in a pivotal U.S. study (REMAIN-1). The company's strategy is built on two complementary platforms: the near-term, device-based Revita and the long-term, gene therapy-based Rejuva, aiming to shift metabolic disease treatment from chronic management to potential one-time cures.

Therapeutic Areas

Other Obesity & Type 2 Diabetes Drugs